title: Gene therapy progress and prospects: fetal gene therapy--first proofs of concept--some adverse effects.
abstract: Somatic gene delivery in utero is a novel approach to gene therapy for genetic disease based on the hypothesis that prenatal intervention may avoid the development of severe manifestations of early-onset disease, allow targeting of otherwise inaccessible tissues including expanding stem cell populations, induce tolerance against the therapeutic transgenic protein and thereby provide permanent somatic gene correction. This approach is particularly relevant in relation to prenatal screening programmes for severe genetic diseases as it could offer prevention as a third option to families faced with the prenatal diagnosis of a genetically affected child. Most investigations towards in utero gene therapy have been performed on mice and sheep fetuses as model animals for human disease and for the application of clinically relevant intervention techniques such as vector delivery by minimally invasive ultrasound guidance. Other animals such as dogs may serve as particular disease models and primates have to be considered in immediate preparation for clinical trials. Proof of principle for the hypothesis of fetal gene therapy has been provided during the last 2 years in mouse models for Crigler Najjar Disease, Leber's congenital amaurosis, Pompe's disease and haemophilia B showing long-term postnatal therapeutic effects and tolerance of the transgenic protein after in utero gene delivery. However, recently we have also observed a high incidence of liver tumours after in utero application of an early form of third-generation equine infectious anaemia virus vectors with SIN configuration. These findings highlight the need for more investigations into the safety and the ethical aspects of in utero gene therapy as well as for science-based public information on risks and benefits of this preventive gene therapy approach before application in humans can be contemplated.
authors.affiliation: Gene Therapy Research Group, Division of Biomedical Sciences, Imperial College London, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Coutelle
authors.forename: M
authors.initials: M
authors.lastname: Themis
authors.forename: S N
authors.initials: SN
authors.lastname: Waddington
authors.forename: S M K
authors.initials: SM
authors.lastname: Buckley
authors.forename: L G
authors.initials: LG
authors.lastname: Gregory
authors.forename: M S
authors.initials: MS
authors.lastname: Nivsarkar
authors.forename: A L
authors.initials: AL
authors.lastname: David
authors.forename: D
authors.initials: D
authors.lastname: Peebles
authors.forename: B
authors.initials: B
authors.lastname: Weisz
authors.forename: C
authors.initials: C
authors.lastname: Rodeck
mesh_terms: D000818:Animals; D005260:Female; D005315:Fetal Diseases / Q000235:genetics / Q000628:therapy*; D005544:Forecasting; D030342:Genetic Diseases, Inborn / Q000196:embryology / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D008113:Liver Neoplasms / Q000209:etiology; D051379:Mice; D023421:Models, Animal; D011247:Pregnancy; D011323:Primates; D012107:Research Design; D012756:Sheep; D019076:Transgenes